Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition and its application

A composition and drug technology, applied in the field of medicine, can solve problems such as the complex pathogenesis of VD

Active Publication Date: 2021-04-30
SHIJIAZHUANG PHARMA GRP NBP PHARMA CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there is no specific drug for the treatment of VD in the world. This is related to the complex pathogenesis of VD. In recent years, there are few new drugs for the clinical treatment of VD. The main researches are on the marketed drugs such as peripheral vasodilators and cholinesterase inhibitors. As well as the application of neuroprotective agents in VD treatment, it is of great significance to find safe, effective and efficient therapeutic drugs to delay and control the development of VD.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and its application
  • Pharmaceutical composition and its application
  • Pharmaceutical composition and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] The preparation of embodiment 1 composition medicinal liquid

[0057]

[0058] Note: *In the pharmaceutical composition, ethyl eicosapentaenoate (C 22 h 34 o 2 ) by weight of eicosapentaenoic acid (C 20 h 30 o 2 ), the values ​​in brackets are based on eicosapentaenoic acid (C 20 h 30 o 2 ) by weight; ethyl docosahexaenoate (C 24 h 36 o 2 ) weight in docosahexaenoic acid (C 22 h 32 o 2 ), the values ​​in brackets are based on docosahexaenoic acid (C 22 h 32 o 2 ) by weight. The same below.

[0059] Preparation of the medicinal solution: take the above-mentioned weight of butylphthalide and omega-3 unsaturated fatty acid derivatives and mix them evenly to obtain the composition medicinal solution. The medicinal liquid of the composition can be further added with pharmaceutically acceptable auxiliary materials, and can be compressed into soft capsules by conventional methods such as the method of CN1623542.

Embodiment 2

[0060] The preparation of embodiment 2 composition medicinal liquid

[0061]

[0062] Preparation of medicinal solution: take the above-mentioned weight of butylphthalide and omega-3 unsaturated fatty acid, mix them evenly, and obtain the composition medicinal solution. The medicinal liquid of the composition can be further added with pharmaceutically acceptable auxiliary materials, and can be compressed into soft capsules by conventional methods such as the method of CN1623542.

Embodiment 3

[0063] The preparation of embodiment 3 composition medicinal liquid

[0064]

[0065]

[0066] Preparation of the medicinal solution: take the above-mentioned weight of butylphthalide and omega-3 unsaturated fatty acid derivatives and mix them evenly to obtain the composition medicinal solution. The medicinal liquid of the composition can be further added with pharmaceutically acceptable auxiliary materials, and can be compressed into soft capsules by conventional methods such as the method of CN1623542.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition and its application, belonging to the technical field of medicine. The pharmaceutical composition comprises butylphthalide and omega-3 unsaturated fatty acid or derivatives thereof. The pharmaceutical composition provided by the present invention has a synergistic effect in the treatment of cerebrovascular disease and dementia, especially nerve damage and vascular dementia caused by ischemic cerebrovascular disease, can significantly increase the therapeutic effect of butylphthalide, reduce the The effective dose of phthalide should be reduced, and the long-term application can reduce the occurrence of adverse reactions.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition containing 3-butyl-l(3H)-isobenzofuranone (butylphthalide) and its application, belonging to the technical field of medicine. Background technique [0002] 3-Butyl-l(3H)-isobenzofuranone, commonly known as butylphthalide, also known as apigenin A, molecular formula C 12 h 14 o 2 , is an active ingredient isolated from celery seeds. Its clinical applications include racemic butylphthalide and L-butylphthalide. The structural formulas are as follows: [0003] [0004] Butylphthalide is a multi-target drug for ischemic cerebrovascular disease. It increases the levels of NO (nitric oxide) and PGI2 (prostacyclin) in the cerebral vascular endothelium, reduces intracellular calcium concentration, inhibits the release of glutamate, Mechanisms such as reducing the content of arachidonic acid, inhibiting oxygen free radicals, and increasing the activity of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/365A61K31/202A61K31/232A61P3/06A61P9/10A61P25/28A61P25/00A61K33/32A61K31/355
CPCA61K31/202A61K31/232A61K31/355A61K31/365A61K33/32A61K2300/00
Inventor 牛锋焦魁良齐军彩韩春景杨蕾赵楠
Owner SHIJIAZHUANG PHARMA GRP NBP PHARMA CO LTD